General Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Curr Pharm Des. 2020;26(10):1025-1035. doi: 10.2174/1381612826666200131103018.
Hyperferritinemia is observed in one-third of patients with non-alcoholic fatty liver disease (NAFLD) and Metabolic Syndrome (MetS). The condition characterized by increased body iron stores associated with components of MetS has been defined as Dysmetabolic Iron Overload Syndrome (DIOS). DIOS represents the most frequent iron overload condition, since it is observed in 15% of patients with MetS and in half of those with NAFLD and its clinical presentation overlaps almost completely with that of dysmetabolic hyperferritinemia (DH). The pathogenetic mechanisms linking insulin resistance (IR), NAFLD and DIOS to iron overload are still debated. Hepcidin seems to play a role in iron accumulation in DIOS and NAFLD patients who show elevated serum hepcidin levels. The iron challenge does not restrain iron absorption despite adequate hepcidin production, suggesting that an impaired hepcidin activity rather than a deficit of hormone production underlies DIOS pathogenesis. Acquired and genetic factors are recognized to contribute to iron accumulation in NAFLD whereas additional studies are required to clearly demonstrate whether the same or different genetic factors lead to iron overload in DIOS. Finally, iron depletion by phlebotomy, together with the modification of diet and life-style habits, represents the therapeutic approach to decrease metabolic alterations and liver enzymes in NAFLD and DIOS patients. In this review, we summarized the current knowledge on the dysregulation of iron homeostasis in NAFLD and DIOS in the attempt to clarify whether they are different or more likely strictly related conditions, sharing the same pathogenic cause i.e. the MetS.
非酒精性脂肪性肝病 (NAFLD) 和代谢综合征 (MetS) 患者中有三分之一存在高血铁蛋白血症。这种特征为体铁储存增加与 MetS 成分相关的情况被定义为代谢性铁过载综合征 (DIOS)。DIOS 代表最常见的铁过载情况,因为它在 15%的 MetS 患者和一半的 NAFLD 患者中观察到,其临床表现与代谢性高血铁蛋白血症 (DH) 几乎完全重叠。将胰岛素抵抗 (IR)、NAFLD 和 DIOS 与铁过载联系起来的发病机制仍存在争议。铁调素似乎在 DIOS 和 NAFLD 患者的铁积累中发挥作用,这些患者表现出血清铁调素水平升高。尽管铁调素产生充足,但铁的摄入不受铁挑战的限制,这表明 DIOS 发病机制是铁调素活性受损而不是激素产生不足。获得性和遗传因素被认为有助于 NAFLD 中的铁积累,而需要进一步的研究来明确表明相同或不同的遗传因素是否导致 DIOS 中的铁过载。最后,通过放血术进行铁耗竭,以及改变饮食和生活方式习惯,代表了降低 NAFLD 和 DIOS 患者代谢改变和肝酶的治疗方法。在这篇综述中,我们总结了目前关于 NAFLD 和 DIOS 中铁稳态失调的知识,试图阐明它们是不同的还是更可能是严格相关的情况,它们具有相同的发病原因,即 MetS。